Your browser doesn't support javascript.
loading
CLL cells cumulate genetic aberrations prior to the first therapy even in outwardly inactive disease phase.
Hernández-Sánchez, María; Kotaskova, Jana; Rodríguez, Ana E; Radova, Lenka; Tamborero, David; Abáigar, María; Plevova, Karla; Benito, Rocío; Tom, Nikola; Quijada-Álamo, Miguel; Bikos, Vasileos; Martín, Ana África; Pal, Karol; García de Coca, Alfonso; Doubek, Michael; López-Bigas, Nuria; Hernández-Rivas, Jesús-María; Pospisilova, Sarka.
Afiliación
  • Hernández-Sánchez M; Hematology Department, Hospital Universitario Salamanca, Salamanca, Spain.
  • Kotaskova J; IBSAL, IBMCC-Cancer Research Center, University of Salamanca, Salamanca, Spain.
  • Rodríguez AE; Center of Molecular Medicine, Central European Institute of Technology, Masaryk University, Brno, Czech Republic.
  • Radova L; Center of Molecular Biology and Gene Therapy, Department of Internal Medicine - Hematology and Oncology, University Hospital Brno and Medical Faculty, Masaryk University, Brno, Czech Republic.
  • Tamborero D; Hematology Department, Hospital Universitario Salamanca, Salamanca, Spain.
  • Abáigar M; IBSAL, IBMCC-Cancer Research Center, University of Salamanca, Salamanca, Spain.
  • Plevova K; Center of Molecular Medicine, Central European Institute of Technology, Masaryk University, Brno, Czech Republic.
  • Benito R; Research Programon Biomedical Informatics, IMIM Hospital del Mar Medical Research Institute and Universitat Pompeu Fabra, Barcelona, Spain.
  • Tom N; Catalan Institution for Research and Advanced Studies (ICREA), Barcelona, Spain.
  • Quijada-Álamo M; Hematology Department, Hospital Universitario Salamanca, Salamanca, Spain.
  • Bikos V; IBSAL, IBMCC-Cancer Research Center, University of Salamanca, Salamanca, Spain.
  • Martín AÁ; Center of Molecular Medicine, Central European Institute of Technology, Masaryk University, Brno, Czech Republic.
  • Pal K; Center of Molecular Biology and Gene Therapy, Department of Internal Medicine - Hematology and Oncology, University Hospital Brno and Medical Faculty, Masaryk University, Brno, Czech Republic.
  • García de Coca A; Hematology Department, Hospital Universitario Salamanca, Salamanca, Spain.
  • Doubek M; IBSAL, IBMCC-Cancer Research Center, University of Salamanca, Salamanca, Spain.
  • López-Bigas N; Center of Molecular Medicine, Central European Institute of Technology, Masaryk University, Brno, Czech Republic.
  • Hernández-Rivas JM; Hematology Department, Hospital Universitario Salamanca, Salamanca, Spain.
  • Pospisilova S; IBSAL, IBMCC-Cancer Research Center, University of Salamanca, Salamanca, Spain.
Leukemia ; 33(2): 518-558, 2019 02.
Article en En | MEDLINE | ID: mdl-30209402
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Leucemia Linfocítica Crónica de Células B / Biomarcadores de Tumor / Aberraciones Cromosómicas / Mutación Tipo de estudio: Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: Leukemia Asunto de la revista: HEMATOLOGIA / NEOPLASIAS Año: 2019 Tipo del documento: Article País de afiliación: España
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Leucemia Linfocítica Crónica de Células B / Biomarcadores de Tumor / Aberraciones Cromosómicas / Mutación Tipo de estudio: Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: Leukemia Asunto de la revista: HEMATOLOGIA / NEOPLASIAS Año: 2019 Tipo del documento: Article País de afiliación: España